Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Best Peptides for SIBO Treatment: Research Comparison

LL-37 (Cathelicidin) Direct antimicrobial activity via bacterial membrane disruption MIC against E. coli and Enterococcus at 2–8 μg/mL; SIBO patients show 58% reduced LL-37 expression Not available as exogenous peptide; upregulated via vitamin D (5000 IU daily

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • LL-37 (Cathelicidin)
  • Direct antimicrobial activity via bacterial membrane disruption
  • MIC against E. coli and Enterococcus at 2–8 μg/mL; SIBO patients show 58% reduced LL-37 expression
  • Not available as exogenous peptide; upregulated via vitamin D (5000 IU daily)
  • Most direct bactericidal effect, but challenging to administer exogenously. Focus on upregulating endogenous production
  • BPC-157
  • Intestinal barrier restoration via tight junction stabilization and angiogenesis
  • Reduced intestinal permeability by 52% in colitis models; accelerates mucosal healing
  • 250–500 mcg subcutaneous or oral daily for 4–8 weeks
  • Best candidate for barrier repair in leaky gut-associated SIBO; strongest preclinical evidence
  • Thymosin Alpha-1
  • Immune modulation; upregulates antimicrobial peptide production
  • Increased serum LL-37 by 34% in immune-compromised patients; reduced infection recurrence in cirrhosis
  • 1.6 mg subcutaneous twice weekly for 12 weeks
  • Addresses systemic immune dysfunction that allows SIBO persistence and relapse
  • KPV
  • Anti-inflammatory; reduces NF-κB activation and bacterial translocation
  • Reduced translocation by 41% in murine colitis models
  • 500 mcg–1 mg oral daily (research context)
  • Emerging data; most relevant for inflammatory SIBO subtypes
  • Dihexa
  • Neurotrophic support for enteric nervous system recovery
  • Enhances BDNF and synaptogenesis; studied in neurological contexts
  • 5–10 mg oral daily (cognitive research dosing)
  • Theoretical application for post-infectious SIBO with MMC dysfunction; minimal direct gut data

Related resources

More comparisons